Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study
Phase 2
- Conditions
- Cannabis WithdrawalOther - Research that is not of generic health relevance and not applicable to specific health categories listed aboveMental Health - Addiction
- Registration Number
- ACTRN12614000248662
- Lead Sponsor
- SW
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Cannabis dependency
Adult
Exclusion Criteria
Poly substance dependence, Co-morbid Mental Health Diagnosis, Intellectual disability, Substance abuse treatment in previous 30 days, Evidence of severe medical condition (cardiac, renal, hepatic), Pregnant women or those wishing to start a family imminently, not willing to abide by NSW Health rules for inpatient admission.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction of number and severity of withdrawal symptoms including-Insomnia, anxiety, agitation, restlessness, low mood.The Cannabis Withdrawal Cale will be used to monitor symptoms.[Day 7 discharge. Patients will be monitored for number of symptoms and withdrawal severity each day using the Cannabis Withdrawal scale. Patients will undergo Urine and blood testing on day 1, day 4 and day 7, then again on day 28.]
- Secondary Outcome Measures
Name Time Method Retention in treatment<br>Abstinence at 28 day followup[Day 7 post admission and again at day 28 post admission.<br>]